DataMeds AI reported a gross margin of 10.91% and a net margin of -496.46% for the quarter ended Mar 2026. These financial ratios cover 10 quarters of results from Dec 2023 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross Margin | -5.86% | 9.19% | 10.06% | 6.38% | 6.49% | 7.67% | -470.23% | 10.91% | ||
| EBT Margin | -1,289.46% | -32.91% | -34.90% | -298.53% | -85.64% | -1,139.04% | -1,667.19% | -496.46% | ||
| EBIT Margin | -1,286.52% | -30.75% | -30.20% | -288.57% | -70.60% | -1,047.11% | -1,517.50% | -385.72% | ||
| EBITDA Margin | -1,286.52% | -30.75% | -30.20% | -288.57% | -70.60% | -1,047.11% | -1,517.50% | -385.72% | ||
| Operating Margin | -1,286.52% | -30.75% | -30.20% | -288.57% | -70.60% | -1,047.11% | -1,517.50% | -385.72% | ||
| Net Margin | -1,289.46% | -32.91% | -34.90% | -298.53% | -85.64% | -1,139.04% | -1,667.19% | -496.46% | ||
| FCF Margin | 740.81% | 18.29% | -21.14% | -12.40% | -26.69% | -37.68% | -376.70% | -218.85% | ||
| Efficiency | ||||||||||
| Inventory AverageInventory Avg. | 9.89M | 9.65M | 8.40M | 7.79M | 8.11M | |||||
| Assets AverageAssets Avg. | 57.70M | 56.14M | 53.50M | 41.62M | 30.29M | |||||
| Invested CapitalInvested Cap. | -2.55M | 10.19M | 18.72M | 27.29M | 24.19M | 35.61M | 11.04M | 12.71M | ||
| Asset Utilization RatioAsset Util. | 0.50 | 0.65 | 0.64 | 0.56 | 0.46 | |||||
| Leverage & Solvency | ||||||||||
| Interest Coverage RatioInterest Cover | -23.75 | -437.75 | -12.68 | -5.44 | -28.64 | -4.65 | -22.13 | -28.95 | -2.90 | |
| Debt Ratio | 1.03 | 0.21 | 0.39 | 0.43 | 0.55 | 0.77 | 0.92 | |||
| Times Interest Earned | -23.75 | -437.75 | -12.68 | -5.44 | -28.64 | -4.65 | -22.13 | -28.95 | -2.90 | |
| Valuation | ||||||||||
| Price to EarningsP/E | -8.19 | -9.17 | -1.92 | -1.02 | -1.48 | |||||
| Price to SalesP/S | 24.44 | 7.85 | 21.90 | 17.00 | 7.35 | |||||
| Price to BookP/B | 59.28 | 67.59 | 9.73 | -2.28 | -0.76 | |||||
| Enterprise Value | 262.99M | 60.77M | 61.75M | 28.35M | 11.41M | |||||
| EV to EBIT | -8.39 | -11.05 | -1.96 | -1.12 | -1.90 | |||||
| EV to EBITDA | -8.39 | -11.05 | -1.96 | -1.12 | -1.90 | |||||
| Market Capitalization | 265.51M | 61.19M | 65.97M | 28.39M | 11.46M | |||||
| Price to FCFP/FCF | -197.04 | -29.43 | -58.11 | -4.51 | -3.36 | |||||
| EV to FCF | -195.18 | -29.23 | -54.39 | -4.51 | -3.34 | |||||
| EV to CFO | -195.18 | -29.23 | -54.39 | -4.51 | -3.34 | |||||
| Return Ratios | ||||||||||
| Return on Sales [ROS]ROS | -1,286.52% | -30.75% | -30.20% | -288.57% | -70.60% | -1,047.11% | -1,517.50% | -385.72% | ||
| Return on Capital Employed [ROCE]ROCE | -326.11% | -308.15% | -347.50% | -791.84% | 3,590.84% | |||||
| Return on Assets [ROA]ROA | -67.95% | -80.69% | -145.33% | -243.33% | -252.81% |